21% LTI!!!

Quote

anonymous

Guest
The 21% long-term incentive (LTI) for 2025 is a significant reason why many employees with potential are considering leaving Bayer. Unfortunately, this situation isn't isolated or limited to just one bad year; we may face several more challenging years ahead, possibly until 2027 or even beyond.

The new women's health product set to launch is embraced as a lifestyle therapy, as the competitors have already shown that it may not be a necessary drug. Bayer, however, plans to launch it with unrealistic expectations as always. Additionally, the DSO experiment has resolved nothing, merely leading to significant job losses without sufficient savings to provide a meaningful bonus.

With raises capped at only 2% and a 21% long-term bonus incentive, it's evident why the company struggles to retain talent. The leadership appears unable to inspire their teams and likely wouldn't secure their positions at other organizations. Given these disappointing incentives, we can expect more capable individuals to seek opportunities elsewhere.
 




anonymous said:
It has to and will get fixed. The STI was robust. No complaints abt this from you?
Click to expand...
It appears that you have not fully comprehended the situation. Perhaps studying finance would help you recognize that this bonus is still inadequate. When you combine a 120% STI with a 20% LTI, you still end up with a 70% bonus. Therefore, there are ample reasons to express dissatisfaction, especially when most pharmaceutical companies bonus well surpasses Bayer’s. Leadership would likely emphasize the positive aspects of the STI, but they will neglect to address the shortcomings of the LTI and merit increase, which will likely result in inadequate compensation for several years. Bayer’s STI is known for its volatility; what may be good this year may be poor next year. Bayer will ensure that this happens with its unrealistic goals on Elinzanetant. Certainly not for the foreseeable future.. All of this occurs due to year after year or poor forecasting, ongoing litigation and poor management. This are the contribution factors 2% merit increases and poor OVERALL BONUSES, which suggests that you are either naïve or foolish to overlook Bayer’s inadequate compensation. If a fix were necessary, when would it occur? Certainly not in the foreseeable future.
 


You’ve raised excellent points! It’s remarkable to see how the STI has fluctuated, especially when reflecting on last year’s less than impressive figure of 37.5%! I guess you can call that volatile…

This is why anyone with any talent looks to get out of here!
 


anonymous said:
It has to and will get fixed. The STI was robust. No complaints abt this from you?
Click to expand...
From what money? Our stocks such, our merit is minimal - one good STI is still a shortfall on the backs of those who actually work for it. We are not in the field and making a quarterly bonus this is ALL we get so lets not lose sight go this not being great. Our LTI is what really should be a sign of poor performance we have waiting years for this payout and people lots thousands$$$. Lets not blurt peoples perceptions with a nice STI that we haven't seen in years.
 















Write your reply...
Top Bottom
Back
Quote